Tiziana Life Sciences – Clinical pipeline update, resolutions seeking shareholder authority to issue new shares for cash & approval of proposed option grant April 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York 21 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has convened a general meeting (the “GM”) to consider proposals to take increased authorities to allot shares; consider the replacement of share option awards and to adopt…

Tiziana Life Sciences #TILS – Develops Novel Investigational Treatment For Patients Infected with COVID-19 April 9, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London — April 9, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it has developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting development…

Tiziana Life Sciences #TILS – Announces Closing of Offering and Resulting Total Voting Rights March 16, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York 16 March 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the closing of its underwritten follow-on public offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. Tiziana issued 3,333,333 ADSs (representing 16,666,665 new ordinary shares…

Alan Green talks market crash, Tiziana Life #TILS, Destiny Pharma #DEST, Open Orphan #ORPH & Cadence Minerals #KDNC on Vox Markets podcast – Posted in: Blog, Open Orphan (ORPH), Tiziana Life Sciences (TILS)

Alan Green discusses the market crash, Tiziana Life #TILS, Destiny Pharma #DEST, Open Orphan #ORPH & Cadence Minerals #KDNC with Justin Waite on the Vox Markets podcast. Interview is 35 minutes 40 seconds in.

Alan Green & Sarah Lowther discuss the market crash, lessons from China, plus an array of stocks including Tiziana Life #TILS & Open Orphan #ORPH on the Total Market Solutions podcast March 15, 2020 – Posted in: Open Orphan (ORPH), Tiziana Life Sciences (TILS)

Friday The 13th & The Weekend Podcast Alan Green Joins Sarah Lowther To Talk All Things Markets During this weekend podcast, and in the wake of a colossal fall, we look at markets which ended the week on Friday the 13th, so far we’ve witnessed an emergency rate cut by the bank of England as the FTSE had its worst day in 33yrs. Alan Green shares some insight on the most recent events surrounding Corona…

Tiziana Life Sciences (Nasdaq: TSLA / AIM: TILS) Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 million March 12, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, March 12, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announced the pricing of its underwritten follow-on public offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares…

Tiziana Life Sciences developing TZLS-501 as a potential treatment for Coronavirus patients March 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

Nasdaq and AIM listed Tiziana Life Sciences plc (Nasdaq: TSLA / AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure. Tiziana, a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, is expediting development of TZLS-501, with Novimmune, SA, a Swiss biotechnology company with whom it entered into a world-wide license for composition-of-matter in 2017.…

Tiziana Life Sciences (Nasdaq: TLSA; AIM: TILS) – TZLS-501 Potential Treatment of Certain Patients Infected with Coronavirus COVID-19 – Posted in: Tiziana Life Sciences (TILS)

New York/London, March 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The Company entered into a world-wide license for composition-of-matter…

Tiziana Life Sciences (TILS) Interim Results for the Six Months Ended 30 June 2019 September 30, 2019 – Posted in: Tiziana Life Sciences (TILS)

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need London, 30 September 2019 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for the six months ended 30 June 2019. Highlights during the period: RESEARCH & DEVELOPMENT CLINICAL PROGRAMMES Foralumab TZLS-401 Foralumab…